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Comparison of Omeprazole and
Pantoprazole Influence on a High
150-mg Clopidogrel Maintenance Dose
The PACA (Proton Pump Inhibitors And
Clopidogrel Association) Prospective Randomized Study
Thomas Cuisset, MD,*†‡ Corinne Frere, MD,†‡ Jacques Quilici, MD,* Raphael Poyet, MD,*
Bénédicte Gaborit, MD,†‡ Laurent Bali, MD,* Olivier Brissy, MD,*
Pierre-Emmanuel Morange, MD, PHD,†‡ Marie-Christine Alessi, MD, PHD,†‡
Jean-Louis Bonnet, MD*
Marseille, France
Objectives This study sought to compare the effect of 2 proton pump inhibitors (PPIs) on platelet response to clopidogrel
after coronary stenting for non–ST-segment elevation acute coronary syndrome (NSTE ACS).
Background Use of omeprazole has been reported to significantly decrease the clopidogrel antiplatelet effect because of cy-
tochrome P450 interaction. Because all PPIs are metabolized by CYP2C19, but to a varying degree, we hypothe-
sized that the reported negative omeprazole–clopidogrel drug interaction may not be caused by a class effect.
Methods A total of 104 patients undergoing coronary stenting for NSTE ACS were prospectively included and randomized
to omeprazole or pantoprazole 20 mg. They received at discharge 75-mg aspirin and 150-mg clopidogrel. Plate-
let reactivity index (PRI) vasoactive stimulated phosphoprotein (VASP) was used to assess clopidogrel response
and adenosine diphosphate (ADP)–induced aggregation for platelet reactivity (ADP-Ag).
Results After 1 month, patients receiving pantoprazole had a significantly better platelet response to clopidogrel as as-
sessed with the PRI VASP: 36  20% versus 48  17% (p  0.007). We identified more clopidogrel nonre-
sponders in the omeprazole group than in the pantoprazole group: 44% versus 23% (p  0.04), odds ratio: 2.6
(95% confidence interval: 1.2 to 6.2). Conversely, we did not observe any significant difference in platelet reac-
tivity with ADP-Ag between the omeprazole and pantoprazole groups: 52  15% and 50  18%, respectively
(p  0.29).
Conclusions The present findings suggest the preferential use of pantoprazole compared with omeprazole in patients receiv-
ing clopidogrel to avoid any potential negative interaction with CYP2C19. (J Am Coll Cardiol 2009;54:
1149–53) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.050t
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beveral studies have shown a broad variability of biological
esponse to clopidogrel and its clinical relevance (1–4).
echanisms underlying this variability of response remain
ontroversial and multiple factors are involved, including
etabolic factors and genetic factors (4). Clopidogrel is a
rodrug, which must be metabolized in the liver to generate
n active metabolite and acquire its antiplatelet properties
5). Accordingly, clopidogrel response has been related to
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ccepted May 4, 2009.he level of activation of the CYP450 (6). Moreover, the
oss-of-function allele of CYP2C19 has been associated
ith a poor response to clopidogrel in both healthy volun-
eers and patients (7–9), and with worse clinical outcomes in
lopidogrel-treated patients (10–12). In addition, medica-
ions metabolized by CYP450, such as omeprazole or
torvastatin, have been shown to influence clopidogrel effect
13,14). Omeprazole has been associated with a lower
fficacy of clopidogrel as assessed by the platelet reactivity
ndex vasoactive stimulated phosphoprotein (PRI VASP)
13). Conversely, new proton pump inhibitors (PPIs) such
s pantoprazole or esomeprazole have shown no effect on
iological response to clopidogrel (15). Because many PPIs
re metabolized by CYP2C19, but to a varying degree, the
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clopidogrel drug interaction may
not be caused by a class effect.
We therefore designed a pro-
spective, randomized study to
compare the influence of ome-
prazole and pantoprazole on the
antiplatelet effect of a high
150-mg maintenance dose of
clopidogrel in patients undergo-
ing coronary stenting for non–
ST-segment elevation acute cor-
onary syndrome (NSTE ACS).
Methods
Study protocol. Consecutive pa-
tients admitted for NSTE ACS
in our institution were eligible
for this prospective study if they
ad undergone successful coronary stenting. We defined
STE ACS as clinical symptoms compatible with acute
yocardial ischemia within 12 h before admission and at
east 1 of the following: a new finding of ST-segment
hanges in at least 2 leads, elevated levels of cardiac markers,
r coronary artery disease as documented by a history of
evascularization or myocardial infarction.
The exclusion criteria were a history of bleeding diathesis,
ersistent ST-segment elevation ACS, New York Heart
ssociation functional class IV, percutaneous intervention
r coronary artery bypass grafting 3 months, contraindi-
ations to antiplatelet therapy, platelet count 100 g/l,
reatinine clearance25 ml/min, use of glycoprotein IIb/IIIa
ntagonist before the procedure, and prior use of PPI or
Figure 1 Design of the Study
ADP  adenosine diphosphate; T0  baseline level; VASP  vasoactive stimulate
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
ADP-Ag  adenosine
diphosphate-induced
aggregation for platelet
reactivity
MFI  median fluorescence
intensity
NSTE ACS  non–ST-
segment elevation acute
coronary syndrome
PPI  proton pump
inhibitor
PRI  platelet reactivity
index
VASP  vasoactive
stimulated phosphoproteinlopidogrel. The design of the study is described in Figure 1.
atients received oral loading doses of 250-mg aspirin and
00-mg clopidogrel at least 12 h before stenting. Initial
latelet parameters were assessed between 12 and 24 h after
he loading dose (T0). Anticoagulation was obtained with
ow-weight molecular heparin (enoxaparin) when possible,
r unfractionated heparin in patients older than 75 years of
ge, or with renal failure. Use of a glycoprotein IIb/IIIa
ntagonist was allowed at the operator’s discretion during
he procedure. Afterward, patients were discharged with the
ollowing dual antiplatelet therapy: 75-mg aspirin and
50-mg clopidogrel daily. Patients were randomized 1:1 to
meprazole 20-mg or pantoprazole 20-mg with randomiza-
ion by sealed envelopes. Platelet tests were performed 1
onth after hospital discharge at clinical follow-up (T1).
he study protocol was approved by the ethics committee of
ur institution, and patients gave written informed consent
or participation.
lood samples and platelet parameters. Blood samples
or testing platelet reactivity were drawn at least 12 h after
he loading dose of aspirin and clopidogrel, and before
dministration of glycoprotein IIb/IIIa antagonist if needed.
he blood–citrate mixture was centrifuged at 120 g for 5
in. The resulting platelet-rich plasma was kept at room
emperature for use within 1 h. The platelet count was
etermined in the platelet-rich plasma sample and adjusted
o 2.5  108 ml1 with homologous platelet-poor plasma.
latelets were stimulated with adenosine diphosphate
ADP) (10 mol/l), and aggregation was assessed with a
AP4 Aggregometer (Biodata Corporation, Wellcome,
aris, France). Aggregation was expressed as the percentage
hange in light transmittance from baseline with platelet-
oor plasma as a reference. Here we report data on maximal
phoprotein.d phos
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September 22, 2009:1149–53 Proton Pump Inhibitor and Clopidogrel Responsentensity of ADP-induced platelet aggregation (ADP-Ag).
he coefficient of variation of maximal intensity of platelet
ggregation with ADP was measured at 6.5%. An ADP-Ag
70% was defined as high post-treatment platelet reactivity
s previously described (3,4,8).
To determine the VASP phosphorylation state of whole
lood, we used a standardized flow cytometric assay (Plate-
et VASP, Diagnostica Stago [Biocytex], Asnières, France),
hich is an adaptation of the method of Schwarz et al. (16).
riefly, a citrated blood sample was incubated with PGE1
r with PGE1 and ADP 10 mol/l for 10 min and fixed
ith paraformaldehyde, after which the platelets were per-
eabilized with nonionic detergent. Analyses were per-
ormed on an EPICS XL-MCL flow cytometer (Beckman
oultronics, Margency, France), the platelet population was
dentified from its forward and side scatter distribution, and
0,000 platelets were gated. A PRI VASP was calculated
rom the median fluorescence intensity (MFI) of samples
ncubated with PGE1 or PGE1 and ADP according to the
ormula: PRI VASP  [(MFI(PGE1)  MFI(PGE1ADP))/
FIPGE1]  100. Clopidogrel nonresponse was defined as
RI VASP 50%.
nd points. The primary end point of the study was
lopidogrel response 1 month after hospital discharge as-
essed with the specific method, PRI VASP. The secondary
nd point was post-treatment platelet reactivity assessed
ith ADP-Ag.
tatistical analysis. Statistical analysis was performed us-
ng the Graphpad Prism Software (version 4.00, Graphpad
oftware, Inc., San Diego, California). We estimated that a
tudy sample size of 100 patients would enable a one-half
tandard deviation difference (10% difference in PRI VASP
etween both groups) to be detected, with an 80% statistical
ower and a 5% alpha risk. Continuous variables are
xpressed as mean  SD. Categorical variables are ex-
ressed as frequencies and percentages. Comparisons be-
ween groups were made with the chi-square or Fisher exact
est for categorical variables and nonparametric statistical
esting (Mann-Whitney) for continuous variables. Values of
 0.05 were considered statistically significant.
esults
total of 104 consecutive patients were prospectively
ncluded and randomized to omeprazole (n  52) or
antoprazole (n  52). Baseline characteristics of the
atients are summarized in Table 1. Baseline levels of
DP-Ag and PRI VASP (T0) were not significantly
ifferent between patients randomized to omeprazole or
antoprazole: 39.5  19% versus 39.8  19% (p  0.84)
nd 35  21% versus 30  21% (p  0.36), respectively.
At 1-month follow-up, in the whole population, mean
RI VASP and ADP-Ag were 41  19% and 51  17%,
espectively. The PRI VASP and ADP-Ag significantly
orrelated (r  0.55, p  0.01). The prevalence of clopi-
ogrel nonresponders was 34% (n  35) with PRI VASP, cnd the rate of high post-treatment platelet reactivity was
2% (n  12).
After 1 month of PPI treatment (T1), patients receiving
antoprazole had a significantly better platelet response to
lopidogrel as assessed with the PRI VASP: 36  20%
ersus 48  17% (p  0.007) (Fig. 2A). The differences of
RI VASP between the 2 measures were significantly
ifferent with pantoprazole and omeprazole: 3.6  15%
ersus 11.2  16%, respectively (p  0.03). We identified
ore clopidogrel nonresponders in the omeprazole group
han in the pantoprazole group: 44% versus 23%, p  0.04,
dds ratio: 2.6 (95% confidence interval: 1.2 to 6.2) (Fig. 3).
We did not observe any significant difference for platelet
eactivity with ADP-Ag between the omeprazole and pan-
oprazole groups: 52  15% and 50  18%, respectively
p  0.29) (Fig. 2B).
iscussion
he present study suggests that the degree of the interaction
etween clopidogrel and PPI is not homogeneous within
he class of PPIs and is less marked with pantoprazole than
ith omeprazole. It confirms that the use of omeprazole
ignificantly reduced the antiplatelet activity of clopidogrel,
ven with a high maintenance dose of clopidogrel, and that
ther PPIs, such as pantoprazole, must be preferred in
aseline Characteristics of the PatientsTable 1 Baseline Characteristics of the Patients
Characteristics
Omeprazole
(n  52)
Pantoprazole
(n  52)
p
Value
Male 47 (90) 43 (82) 0.25
Age (yrs) 64.5 12 62.5 13 0.34
Body mass index (kg/m2) 26.4 4 26.1 5 0.30
Cardiovascular risk factors
Hypertension 34 (65) 22 (42) 0.02
Diabetes mellitus 11 (21) 11 (21) 1.00
Smoker 21 (40) 24 (46) 0.55
Dyslipidemia 28 (53) 28 (54) 1.00
Familial history 17 (33) 11 (21) 0.19
Discharge medications
Statins 36 (69) 40 (77) 0.78
Beta-blocker 37 (71) 44 (84) 0.10
Calcium-channel blockers 10 (19) 8 (15) 0.60
Ejection fraction 10 (19) 8 (15) 0.60
Biological data
Creatinine (mg/dl) 96 11 100 17 0.67
CRP (mmol/l) 2.4 0.8 2.7 0.5 0.68
Platelet count 214 33 227 45 0.60
ADP-Ag T0 (%) 39.5 19 39.8 19 0.84
PRI VASP T0 (%) 35 21 30 21 0.36
Procedural data
Glycoprotein IIb/IIIa antagonists 23 (44) 28 (54) 0.37
Drug-eluting stent 18 (35) 17 (33) 0.78
alues are mean  SD for quantitative variables and n (%) for qualitative variables.
ADP-Ag  adenosine diphosphate-induced aggregation for platelet reactivity; CRP  C-reactive
rotein; PRI VASP platelet reactivity index vasoactive stimulated phosphoprotein; T0 baseline
evel.lopidogrel-treated patients. Interestingly, the PPI had no
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Proton Pump Inhibitor and Clopidogrel Response September 22, 2009:1149–53ignificant effect on platelet reactivity assessed with ADP-
g, whereas omeprazole significantly blunted the decrease
n PRI VASP with clopidogrel. This finding underlined the
ivergence between the 2 tests: ADP-Ag, despite the use of
DP stimulation, may reflect other platelet pathways,
hereas levels of VASP phosphorylation/dephosphorylation ac-
urately reflect P2Y12 inhibition/activation (16). Biological
tudies have shown a broad interindividual variability of
latelet response to clopidogrel, and more recently, a low
esponse to clopidogrel has been associated with an in-
reased risk of ischemic events (1–4) and is now a growing
oncern in the medical community. Several mechanisms
ave been proposed to explain this variability of response,
ncluding genetic factors, metabolic parameters, or interac-
ion with other medications (1).
The active metabolite of clopidogrel, which irreversibly
locks platelet ADP P2Y12 receptors, arises from complex
iochemical reactions involving several CYP450 isoforms
5). Lau et al. (6) reported that CYP3A4 metabolic activity
Figure 2 Platelet Parameters and
According to Proton Pump Inhibitors
Clopidogrel response with platelet reactivity index vasoactive stimulated phos-
phoprotein (PRI VASP) (A) and platelet reactivity with adenosine diphosphate–
induced platelet aggregation (ADP-Ag) (B) according to proton pump inhibitor
treatment.orrelated with between-subject variability in clopidogrelesponse. The CYP450 isoform 2C19 plays a major role in
his metabolism, and its activity dramatically influences the
ntiplatelet effect of clopidogrel. This effect has been high-
ighted recently with the loss-of-function CYP2C19*2 al-
ele, associated with a low response to clopidogrel and worse
linical outcome (7–12). Several medications are also me-
abolized by CYP450, suggesting potential drugs–
lopidogrel interactions. Accordingly, interaction between
torvastatin or omeprazole and clopidogrel has been sug-
ested in biological studies (13,14). Gilard et al. (13)
howed a significant interaction between omeprazole and
lopidogrel with a decreased platelet response to clopidogrel
ssessed with PRI VASP after omeprazole administration.
ndeed, omeprazole is both a substrate and an inhibitor of
YP2C19. In contrast, in a recent study, Siller-Matula et al.
15) found no interaction between new PPIs (esomeprazole
r pantoprazole) and clopidogrel response in patients with
oronary artery disease. These findings suggested the pref-
rential use of new PPIs such as pantoprazole, which are less
otent CYP2C19 inhibitors than omeprazole.
The biological interaction found between atorvastatin
nd clopidogrel did not show any clinical effect while the
nteraction was tested in large randomized trials (17,18).
wo clinical reports have suggested a clinical relevance of
PI and clopidogrel interaction. Indeed, Juurlink et al. (19)
uggested that among patients receiving clopidogrel after an
cute myocardial infarction, concomitant therapy with a
PI other than pantoprazole was associated with a loss of
he beneficial effects of clopidogrel and an increased risk of
einfarction. More recently, in a retrospective cohort study
f 8,205 patients with ACS taking clopidogrel, concomitant
se of clopidogrel and PPI after hospital discharge for ACS
as also associated with an increased risk of adverse out-
omes than use of clopidogrel without PPI, confirming that
se of PPI may be associated with attenuation of the
enefits of clopidogrel after ACS (20). These results sug-
ested the clinical relevance of a biological interaction
p=0.04
Omeprazole Pantoprazole
0
10
20
30
40
P
re
va
le
n
ce
 o
f 
C
lo
p
id
o
g
re
l
N
o
n
 R
es
p
o
n
d
er
s 
(%
)
Figure 3 Prevalence of Clopidogrel Nonresponders
Prevalence of clopidogrel nonresponders (platelet reactivity index vasoactive
stimulated phosphoprotein 50%) according to proton pump inhibitor
treatment.
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September 22, 2009:1149–53 Proton Pump Inhibitor and Clopidogrel Responseetween most PPIs (e.g., omeprazole) and clopidogrel. Our
resent study confirms the difference between 2 different
PIs in terms of modulation of clopidogrel response. This is
f great importance for daily practice because PPIs are now
standard of care for patients receiving dual-antiplatelet
herapy to prevent gastrointestinal bleeding. Indeed, PPIs
re recommended to prevent the risk of gastrointestinal
leeding in the latest American recommendations (21).
tudy limitations. The main limitations of the present
tudy include its small sample size and biological contents
ithout clinical data. Additional large prospective clinical
tudies are required to confirm the clinical effect of this
iological interaction.
onclusions
he lack of negative effects of concomitant treatment with
antoprazole is an important finding because it may have an
mpact on clinical practice and suggests the preferential use
f pantoprazole as PPI in patients receiving clopidogrel to
void any potential negative interaction as described for
meprazole (13,19,20).
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